1+ day, 16+ hour ago   (273+ words) An expert panel moderated by Sara Nunnery, MD, of Tennessee Oncology, convened to discuss how they choose therapy beyond the first-line setting for patients with ESR1-mutated disease. Dr. Nunnery was joined by Nan Chen, MD, of the University of Chicago;…...

3+ day, 11+ hour ago   (290+ words) Jeffrey Hyams, MD, of the University of Connecticut and Connecticut Children’s Hospital in Hartford, Connecticut, shares results from the UNIFI JR trial evaluating ustekinumab in pediatric patients with ulcerative colitis who did not respond to conventional therapies. From these results…...

3+ day, 11+ hour ago   (296+ words) Dr. Iorio: My name is Raffaele Iorio. I’m an associate professor of neurology at the Universita Cattolica del Sacro Cuore in Rome, Italy. I am also a staff neurologist at the Fondazione Policlinico Gemelli in Rome, Italy. Rare Diseases Today:…...

1+ week, 6+ hour ago   (336+ words) Investigators led by Hope S. Rugo, MD, of City of Hope Comprehensive Cancer Center, recently published safety and patient-reported outcome (PRO) data from TROPION-Breast01 that “complement the improvements in efficacy demonstrated with Dato-DXd versus ICC, supporting Dato-DXd as a treatment option…...

1+ week, 5+ day ago   (350+ words) Cindy Zadikoff, MD, MSc, executive medical director at AbbVie, discusses recent results of the TEMPO-2 trial. Here, she shares what tavapadon use means for clinicians treating early Parkinson’s disease, how to balance tolerability and efficacy in clinical practice, the drug’s…...

3+ week, 2+ day ago   (155+ words) I-STRONG, a novel intervention program for adolescent patients with sickle cell disease (SCD), offers an effective approach to chronic pain management based on a pilot study published in Blood Advances.1 Researchers at children’s hospitals in Atlanta and Cincinnati conducted a…...

3+ week, 3+ day ago   (283+ words) In patients with essential thrombocythemia (ET), the condition may feature calreticulin mutations that ET therapies can target. INCA033989, a novel monoclonal antibody in development for ET, operates in this manner, and a first-in-human phase 1 study evaluating this agent has yielded encouraging…...

3+ week, 4+ day ago   (226+ words) Therapies currently used to treat myasthenia gravis (MG) are limited by their short-term efficacy and may not be readily available in plasma exchange settings. In light of this, other approaches to treating MG are needed. In a prospective study published…...

3+ week, 4+ day ago   (221+ words) The study, conducted in the second year of vaccine distribution, included 639 individuals selected from the German general population. Participants had a mean age of 37.04 years, 77.8% were female, and 24.4% self-reported a mental illness. Initially, 715 individuals participated in the study, but 76 were…...